About the Authors
- Linda L. Kusner
-
* E-mail: lkusner@gwu.edu
Affiliation Department of Pharmacology and Physiology, George Washington University, Washington, District of Columbia, United States of America
- Michael J. Ciesielski
-
Affiliations Department of Neurosurgery, Roswell Park Cancer Institute, Buffalo, New York, United States of America, Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, United States of America
- Alexander Marx
-
Affiliation Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany
- Henry J. Kaminski
-
Affiliation Department of Neurology, George Washington University, Washington, District of Columbia, United States of America
- Robert A. Fenstermaker
-
Affiliations Department of Neurosurgery, Roswell Park Cancer Institute, Buffalo, New York, United States of America, Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York, United States of America
Competing Interests
The authors acknowledge that the authors Michael Ciesielski and Robert Fenstermaker have a conflict of interest based on this manuscript. They hold the patent to SVN53-67/M57-KLH, the vaccine used in the study. They are co-founders of MimiVax, LLC which was developed with the purpose of commercializing the SVN53-67/M57-KLH. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: LLK MJC AM HJK RAF. Performed the experiments: LLK MJC AM. Analyzed the data: LLK MJC AM HJK RAF. Contributed reagents/materials/analysis tools: MJC AM HJK RAF. Wrote the paper: LLK HJK RAF.